UPDATE: Credit Suisse Initiates Infinity Pharmaceuticals at Outperform on Risk/Reward
Credit Suisse initiated coverage on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) with a Outperform rating and a $42.00 price target.
Credit Suisse commented, "We believe that the next steps in the development of IPI-145 are lower risk than typical for a drug at its stage, and expect IPI-145 to emerge as a best-in-class PI3K inhibitor. We also view the target markets as able to support several multibillion dollar drugs, and expect that IPI-145 could capture a meaningful share. While higher risk, earlier stage, and less investible than its larger pier PCYC, we believe that risk/reward for INFI remains favorable."
Infinity Pharmaceuticals closed at $32.93 on Monday.
Latest Ratings for INFI
|Jun 2016||William Blair||Downgrades||Outperform||Market Perform|
|Jun 2016||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.